Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA)
Ludger Klimek,Natalija Novak,Eckard Hamelmann,Thomas Werfel,Martin Wagenmann,Christian Taube,Andrea Bauer,Hans Merk,Uta Rabe,Kirsten Jung,Wolfgang Schlenter,Johannes Ring,Adam Chaker,Wolfgang Wehrmann,Sven Becker,Norbert Mülleneisen,Katja Nemat,Wolfgang Czech,Holger Wrede,Randolf Brehler,Thomas Fuchs,Thilo Jakob,Tobias Ankermann,Sebastian M Schmidt,Michael Gerstlauer,Christian Vogelberg,Thomas Zuberbier,Karin Hartmann,Margitta Worm
DOI: https://doi.org/10.1007/s40629-020-00160-4
Abstract:Two employees of the National Health Service (NHS) in England developed severe allergic reactions following administration of BNT162b2 vaccine against COVID-19 (coronavirus disease 2019). The British SmPC for the BNT162b2 vaccine already includes reference to a contraindication for use in individuals who have had an allergic reaction to the vaccine or any of its components. As a precautionary measure, the Medicines and Healthcare products Regulatory Agency (MHRA) has issued interim guidance to the NHS not to vaccinate in principle in "patients with severe allergies". Allergic reactions to vaccines are very rare, but vaccine components are known to cause allergic reactions. BNT162b2 is a vaccine based on an mRNA embedded in lipid nanoparticles and blended with other substances to enable its transport into the cells. In the pivotal phase III clinical trial, the BNT162b2 vaccine was generally well tolerated, but this large clinical trial, used to support vaccine approval by the MHRA and US Food and Drug Administration, excluded individuals with a "history of a severe adverse reaction related to the vaccine and/or a severe allergic reaction (e.g., anaphylaxis) to a component of the study medication". Vaccines are recognized as one of the most effective public health interventions. This repeated administration of a foreign protein (antigen) necessitates a careful allergological history before each application and diagnostic clarification and a risk-benefit assessment before each injection. Severe allergic reactions to vaccines are rare but can be life-threatening, and it is prudent to raise awareness of this hazard among vaccination teams and to take adequate precautions while more experience is gained with this new vaccine.